- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01724645
Beneficial Effects of Korean Traditional Diets in Subjects With Hypertension and Type 2 Diabetes
Randomized, Open Label, Parallel Controlled, to Evaluate the Beneficial Effects of Korean Traditional Dites in Subjects With Hypertension and Type 2 Diabetes.
This trial is being conducted to look for following changes when Korean traditional diets is taken in subjects with hypertension and type 2 diabetes:
To evaluate the improvement of the controlling fasting blood glucose and glycated hemoglobin.
To assess the controlling blood pressure and heart rate.
To evaluate the influence on cardiovascular risk factor, Triglyceride, cholesterol, High Density Lipoprotein-cholesterol and Low-Density Lipoprotein-cholesterol.
To evaluate the influence on Gamma-Glutamyl Transpeptidase.
To evaluate the influence on Cardiovascular risk factor.
To evaluate the influence on valsava score, breathing score and upright score.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Jeollabuk-do
-
Jeonju, Jeollabuk-do, Korea, republiek van, 560-822
- Clinical Trial Center for Functional Foods; Chonbuk National University Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Subjects who are men and women volunteers 19~80years
- Subject who have hypertension and type 2diabetes.
- Subject who have taking oral medications :
(hypoglycemic, blood pressure and lipid modifying drugs).
- Subject must provide written informed consent to participate in the study.
Exclusion Criteria:
- Subject with a history or evidence of clinically significant gastrointestinal,anorectal, hepatic, renal, neurological, pulmonary, endocrine, blood tumor,psychiatric.
- Hypertension(DBP>116mmHg or SBP>200 mmHg) having the history of cardiovascular events or taking medications known to affect lipoprotein metabolism.
- Having Type 1 diabetes mellitus or uncontrolled Type 2 diabetes mellitus (HbA1c >9.0%).
- Subjects with the history of cancer.
- Subjects who have a gastrointestinal (GI) disease (Crohn's disease, etc.) that would increase the influence with absorbance medication or a GI surgery excluding appendectomy and hernia surgery.
- Having digestive, or central nervous system disorders.
- Subject is hematologic, or neuroretinopathy.
- Subject with uterine fibroids at ultrasonography.
- Having severe or malignant retinopathy.
- Having the impairment of renal and liver function, dysproteinemia, nephritic syndrome, or other renal disease.
- Having coagulopathy
- Having human immunodeficiency virus.
- Having the history of mental instability and of drug and alcohol.
- Having the history of reactions to our experimental products.
- Participating in other clinical trials within the past 2 months.
- Having laboratory tests, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study.
- Having the history of alcohol or substance abuse.
- Subject is pregnant, planning to become pregnant, or breast-feeding.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Korean traditional diets
Korean traditional diets (calorie 2,100kcal) for 12weeks
|
The consumption of Korean traditional diets reflecting the characteristics of Korean traditional diets without the limitation of calories has an effect on control of cardiovascular risk factor, so this study instructed all subjects of the intervention group to consume about 2,100kcal of served meals freely. The Korean Traditional diets, which encourages the intake of cooked rice, vegetables,soup,Kimchi and soy fermented foods.
Andere namen:
|
Actieve vergelijker: Control group
Control group : told to "eat as usal diet) for 12weeks
|
Told to " eat as usal diets".
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
HbA1C :Glycated Hemoglobin
Tijdsspanne: 84days
|
Glycated Hemoglobin is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
TG :Triglycerides
Tijdsspanne: 84days
|
Triglycerides is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
TC :Total cholesterol
Tijdsspanne: 84days
|
Total cholesterol is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
HDL-C :High Density Lipoprotein-Cholesterol
Tijdsspanne: 84days
|
HDL-C is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
LDL-C : Low Density Lipoprotein-Cholesterol
Tijdsspanne: 84days
|
LDL-C is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
Breathing score
Tijdsspanne: 84days
|
Breathing score is measured in study visits to the clinic, week 0(baseline)and week 12.
|
84days
|
Valsalva score
Tijdsspanne: 84days
|
Valsalva score is measured in study visits to the clinic, week 0(baseline)and week 12.
|
84days
|
Upright score
Tijdsspanne: 84days
|
Upright score is measured in study visits to the clinic, week 0(baseline) and week 12.
|
84days
|
ApoA1 :Apolipoprotein A1
Tijdsspanne: 84days
|
Apolipoprotein A1 is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
ApoB :Apolipoprotein B
Tijdsspanne: 84days
|
Apolipoprotein B is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
Apo E :Apolipoprotein E
Tijdsspanne: 84days
|
Apolipoprotein E is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
Free fatty acid
Tijdsspanne: 84days
|
Free fatty acid is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
Adiponectin
Tijdsspanne: 84days
|
Adiponectin is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
PAI-1 :Plasminogen activator inhibitor type 1
Tijdsspanne: 84days
|
PAI-1 is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
Homocysteine
Tijdsspanne: 84days
|
Homocysteine is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
FPG :Fasting plasma glucose
Tijdsspanne: 84days
|
Fasting plasma glucose is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
DBP:Diastolic Blood Pressure
Tijdsspanne: 84days
|
DBP is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
SBP:Systolic Blood Pressure
Tijdsspanne: 84days
|
SBP is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
Heart rate
Tijdsspanne: 84days
|
Heart rate is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
weight
Tijdsspanne: 84days
|
weight is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
BMI:Body Mass Index
Tijdsspanne: 84days
|
BMI is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
Body fat percent
Tijdsspanne: 84days
|
Body fat percent is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
Waist
Tijdsspanne: 84days
|
Waist is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
Obesity associated gut microbiome(Bacteriodetes)
Tijdsspanne: 84days
|
Bacteriodetes is measured in study visits to the clinic, week 0(baseline)and week 12.
|
84days
|
Obesity associated gut microbiome(Firmicutes)
Tijdsspanne: 84days
|
Firmicutes is measured in study visits to the clinic, week 0(baseline)and week 12.
|
84days
|
Hypoglycemic(oral medication)
Tijdsspanne: 84days
|
Hypoglycemic oral medication is measured in study 0wk, 4wk, 8wk and 12wk.
|
84days
|
Control blood pressure(oral medication)
Tijdsspanne: 84days
|
Control blood pressure(oral medication) is measured in study 0wk, 4wk, 8wk and 12wk.
|
84days
|
Lipid modifying (oral medication)
Tijdsspanne: 84days
|
Lipid modifying (oral medication) is measured in study 0wk, 4wk, 8wk and 12wk.
|
84days
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CUH_KOREAN-FOOD_2-2_2010
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Diabetes mellitus, type 2
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationWervingDiabetes mellitus type 2 met complicatiesIndië
-
SanofiVoltooidDiabetes mellitus type 1 - Diabetes mellitus type 2Hongarije, Russische Federatie, Duitsland, Polen, Japan, Verenigde Staten, Finland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...Voltooid
-
AstraZenecaWerving
-
Daewoong Pharmaceutical Co. LTD.Nog niet aan het wervenT2DM (diabetes mellitus type 2)
-
Zhongda HospitalWervingDiabetes mellitus type 2 (T2DM)China
-
Newsoara Biopharma Co., Ltd.WervingT2DM (diabetes mellitus type 2)China
-
Shanghai Golden Leaf MedTec Co. LtdActief, niet wervendDiabetes mellitus type 2 (T2DM)China
-
SanofiVoltooid
-
Haisco Pharmaceutical Group Co., Ltd.VoltooidT2DM (diabetes mellitus type 2)China
Klinische onderzoeken op Korean traditional diets
-
Mondelēz International, Inc.KGK Science Inc.Voltooid
-
University of Texas at AustinLone Star Circle of CareVoltooidMetaboolsyndroom | Type 2 diabetes | Pre-diabetesVerenigde Staten
-
Wolfson Medical CenterBeëindigdColitis ulcerosaIsraël, Frankrijk, Italië
-
University of CalgaryStewart Diabetes Education FundVoltooidObesitas | Diabetes mellitus type 2Canada
-
Cairo UniversityWervingObesitas | Prikkelbare Darm Syndroom | Abdominale obesitasEgypte
-
Fondazione Valter LongoUniversity of Palermo; University of Calabria; Regione Calabria / Comune Varapodio en andere medewerkersWervingRisicogedrag | Obesitas | OvergewichtItalië
-
Vegenat, S.A.OnbekendEnterale voeding | Acute ontsteking aan de alvleesklierSpanje
-
Vegenat, S.A.VoltooidHyperglykemie | Kritieke ziekte | Mechanische beademingscomplicatie | Dieet Wijziging | Metabole stress hyperglykemieSpanje
-
University of California, DavisUSDA, Western Human Nutrition Research CenterWerving
-
International Centre for Diarrhoeal Disease Research...Werving